Radiolabeled peptides with positron-emitting radiometals including 68Ga, 86Y, and 64Cu have been used in targeted Positron Emission Tomography (PET) imaging of SSTR2, a receptor highly expressed in neuroendocrine tumors (NETs) [1–4]. The gene discussed is SSTR2; the disease is neuroendocrine neoplasm.